These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35141703)

  • 1. Diet-Induced Non-alcoholic Fatty Liver Disease and Associated Gut Dysbiosis Are Exacerbated by Oral Infection.
    Simas AM; Kramer CD; Genco CA
    Front Oral Health; 2021; 2():784448. PubMed ID: 35141703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of
    Wang T; Ishikawa T; Sasaki M; Chiba T
    Front Med (Lausanne); 2022; 9():822190. PubMed ID: 35308549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
    Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
    World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Pathobiont-Induced Changes in Gut Microbiota Aggravate the Pathology of Nonalcoholic Fatty Liver Disease in Mice.
    Yamazaki K; Kato T; Tsuboi Y; Miyauchi E; Suda W; Sato K; Nakajima M; Yokoji-Takeuchi M; Yamada-Hara M; Tsuzuno T; Matsugishi A; Takahashi N; Tabeta K; Miura N; Okuda S; Kikuchi J; Ohno H; Yamazaki K
    Front Immunol; 2021; 12():766170. PubMed ID: 34707622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral infection with a periodontal pathogen alters oral and gut microbiomes.
    Simas AM; Kramer CD; Weinberg EO; Genco CA
    Anaerobe; 2021 Oct; 71():102399. PubMed ID: 34090994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease.
    Jennison E; Byrne CD
    Clin Mol Hepatol; 2021 Jan; 27(1):22-43. PubMed ID: 33291863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease.
    Yoneda M; Naka S; Nakano K; Wada K; Endo H; Mawatari H; Imajo K; Nomura R; Hokamura K; Ono M; Murata S; Tohnai I; Sumida Y; Shima T; Kuboniwa M; Umemura K; Kamisaki Y; Amano A; Okanoue T; Ooshima T; Nakajima A
    BMC Gastroenterol; 2012 Feb; 12():16. PubMed ID: 22340817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NOD2 in hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice.
    Cavallari JF; Pokrajac NT; Zlitni S; Foley KP; Henriksbo BD; Schertzer JD
    Am J Physiol Endocrinol Metab; 2020 Aug; 319(2):E305-E314. PubMed ID: 32516028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.
    Quesada-Vázquez S; Aragonès G; Del Bas JM; Escoté X
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endotoxemia by
    Sasaki N; Katagiri S; Komazaki R; Watanabe K; Maekawa S; Shiba T; Udagawa S; Takeuchi Y; Ohtsu A; Kohda T; Tohara H; Miyasaka N; Hirota T; Tamari M; Izumi Y
    Front Microbiol; 2018; 9():2470. PubMed ID: 30405551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model.
    Li H; Wang Q; Chen P; Zhou C; Zhang X; Chen L
    Front Pharmacol; 2021; 12():788558. PubMed ID: 34938193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral Administration of Porphyromonas gingivalis Alters the Gut Microbiome and Serum Metabolome.
    Kato T; Yamazaki K; Nakajima M; Date Y; Kikuchi J; Hase K; Ohno H; Yamazaki K
    mSphere; 2018 Oct; 3(5):. PubMed ID: 30333180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct roles for dietary lipids and Porphyromonas gingivalis infection on atherosclerosis progression and the gut microbiota.
    Kramer CD; Simas AM; He X; Ingalls RR; Weinberg EO; Genco CA
    Anaerobe; 2017 Jun; 45():19-30. PubMed ID: 28442421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIRT3 Deficiency Promotes High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis.
    Chen M; Hui S; Lang H; Zhou M; Zhang Y; Kang C; Zeng X; Zhang Q; Yi L; Mi M
    Mol Nutr Food Res; 2019 Feb; 63(4):e1800612. PubMed ID: 30525304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
    Wang P; Wang J; Li D; Ke W; Chen F; Hu X
    J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal sucralose intake alters gut microbiota of offspring and exacerbates hepatic steatosis in adulthood.
    Dai X; Guo Z; Chen D; Li L; Song X; Liu T; Jin G; Li Y; Liu Y; Ajiguli A; Yang C; Wang B; Cao H
    Gut Microbes; 2020 Jul; 11(4):1043-1063. PubMed ID: 32228300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
    Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
    Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
    Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.